Difference between revisions of "Treating COVID-19 with Chloroquine"

From OmniJournal
Jump to navigation Jump to search
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://academic.oup.com/jmcb/article/12/4/32...")
 
 
Line 27: Line 27:
 
== Major Issues ==
 
== Major Issues ==
  
No major issues identified.  
+
No major issues identified at this time.  
  
 
== Minor Issues ==
 
== Minor Issues ==
  
No minor issues identified.
+
No minor issues identified at this time.
  
 
== Impact ==
 
== Impact ==

Latest revision as of 17:08, 22 July 2020

Publication
Title
Authors
  • Mingxing Huang
  • Tiantian Tang
  • Pengfei Pang
  • ...
  • Hong Shan
Journal Journal of Molecular Cell Biology
Date April 1, 2020

Randomized controlled trial of 22 COVID-19 positive, symptomatic patients treated with either chloroquine 500mg twice daily or Lopinavir/Rotinavir 400/100mg twice daily for 10 days.

All chloroquine treated patients were PCR negative for SARS-CoV-2 by day 13 and 92% of Lopinavir/Rotinavir treated patients were PCR negative by day 14. All chloroquine treated patients were discharged from the hospital by day 14 compared to only 50% of Lopinavir/Rotinavir treated patients.

Of note, the average time from symptom onset to treatment was 2.5 days and 6.5 days in the chloroquine and Lopinavir/Rotinavir groups, respectively (P = < 0.001). This study suggests potential efficacy of chloroquine in treatment of early stage COVID-19 disease.

Major Issues

No major issues identified at this time.

Minor Issues

No minor issues identified at this time.

Impact

This study both supported earlier findings that lopinavir/rotinavir is likely ineffective in treatment of COVID-19 and that early treatment with chloroquine may have efficacy.

Article Revisions

None at this time.

References